Bavarian Nordic (BAVA)

Copenhagen
Currency in DKK
173.2
+1.7(+0.99%)
Closed·
BAVA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
BAVA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
170.0174.0
52 wk Range
123.3300.0
Key Statistics
Edit
Prev. Close
171.5
Open
172
Day's Range
170-174
52 wk Range
123.3-300
Volume
271.11K
Average Vol. (3m)
292.85K
1-Year Change
-4.06%
Book Value / Share
148.52
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BAVA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
267.5
Upside
+54.45%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth
Show more

Bavarian Nordic Company Profile

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Employees
1645
Market
Denmark

Bavarian Nordic Earnings Call Summary for Q1/2025

  • Q1 2025 revenue up 62% YoY to 1,347M DKK; stock jumps 9.83% post-earnings
  • Strong growth in Public Preparedness (+83% YoY) and Travel Health (+52% YoY) segments
  • Chikungunya vaccine launched in US, approved in Europe and UK; European launch pending
  • Full-year guidance maintained: revenue 5.7-6.0B DKK, EBITDA margin 26-30%
  • $144M BARDA order negotiation ongoing; robust order backlog supports future growth
Last Updated: 05/09/2025, 08:57 AM
Read Full Transcript

Compare BAVA to Peers and Sector

Metrics to compare
BAVA
Peers
Sector
Relationship
P/E Ratio
10.1x−5.7x−0.5x
PEG Ratio
0.33−0.200.00
Price / Book
1.2x1.9x2.6x
Price / LTM Sales
2.1x6.5x3.0x
Upside (Analyst Target)
56.0%715.6%52.7%
Fair Value Upside
Unlock8.0%7.6%Unlock

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 267.5
(+54.45% Upside)

Earnings

Latest Release
May 09, 2025
EPS / Forecast
2.82 / --
Revenue / Forecast
1.35B / --
EPS Revisions
Last 90 days

People Also Watch

1,375.0
GMAB
+2.69%
1,598.0
DSV
+0.76%
456.6
NOVOb
+0.11%
1,212.5
PNDORA
0.00%
12,625
MAERSKb
-0.63%

FAQ

What Is the Bavarian Nordic (BAVA) Stock Price Today?

The Bavarian Nordic stock price today is 173.20

What Stock Exchange Does Bavarian Nordic Trade On?

Bavarian Nordic is listed and trades on the Copenhagen Stock Exchange stock exchange.

What Is the Stock Symbol for Bavarian Nordic?

The stock symbol for Bavarian Nordic is "BAVA."

What Is the Bavarian Nordic Market Cap?

As of today, Bavarian Nordic market cap is 13.44B.

What Is Bavarian Nordic's Earnings Per Share (TTM)?

The Bavarian Nordic EPS (TTM) is 16.66.

When Is the Next Bavarian Nordic Earnings Date?

Bavarian Nordic will release its next earnings report on Aug 22, 2025.

From a Technical Analysis Perspective, Is BAVA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Bavarian Nordic Stock Split?

Bavarian Nordic has split 5 times.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.